From GlobeNewswire: 2025-05-27 08:35:00

Predictive Oncology Inc. (NASDAQ: POAI) issues a statement regarding its dispute with Renovaro, Inc. The Delaware Court of Chancery rejected RENB’s request for an expedited trial in July, setting trial for November 12-13, 2025. POAI intends to defend against claims by RENB and looks forward to its day in Court. Predictive Oncology is a leader in AI-driven drug discovery, using its AI platform, PEDAL, to predict tumor response to drug compounds with 92% accuracy. The company offers one of the industry’s broadest AI-based drug discovery solutions and is headquartered in Pittsburgh, PA.

Investor Relations Contact: Mike Moyer, LifeSci Advisors, LLC, [email protected]. Certain statements in this press release are forward-looking. Predictive Oncology’s actual future performance may differ from these statements due to various factors, as discussed in filings with the SEC. The company disclaims any intent or obligation to update these statements and does not guarantee the achievement of expectations.



Read more at GlobeNewswire: Court Denies Renovaro Motion for an Expedited Trial in